Latest news for Shapeways Holdings (OTC:SHPSQ) Stock

Shapeways Holdings Inc is a leading digital manufacturer combining high quality, flexible on-demand manufacturing with purpose-built proprietary software to offer customers an end-to-end digital manufacturing platform on which they can rapidly transform digital designs into physical products. It makes industrial-grade additive manufacturing accessible by fully digitizing the end-to-end manufacturing process. The Company reports in one segment, which focuses on providing additive manufacturing services to customers.

Shapeways Holdings Inc Warrants (31/10/2026)

Shapeways Holdings Inc

Carnival Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) is charting a multi-year growth path and JPMorgan analyst Matthew R. Boss sees <a href="https://www.benzinga.com/topic/cruise-lines">the cruise giant</a> setting sail for stronger returns in 2025 and beyond.
After an exclusive shipboard chat with Carnival's top brass, Boss highlights key catalysts that could drive the next leg of the stock's performance.
<h2 class="wp-block-heading">Growth Beyond The Horizon</h2>
CEO Josh Weinstein sees Carnival's diversified portfolio of eight brands as a key advantage over smaller peers, with Carnival and AIDA already surpassing 2019 performance metrics. The real opportunity? The remaining six brands, many still trailing pre-pandemic levels, are now under Weinstein's direct oversight after organizational shifts. With a focus on marketing and execution, management is counting on a strong 2025-2026 ramp-up.
While the industry worries about overcapacity, Carnival is taking a disciplined approach, adding just 0-1% annual capacity growth, well below the pre-pandemic 3%. With only 2-3% of global hotel stays coming from cruises, the U.S. and Canada remain a largely untapped market.
Read Also: <a href="https://www.benzinga.com/24/12/42657003/analysts-see-smooth-sailing-for-carnival-as-q4-results-beat-expectations">After Carnival&#8217;s Q4 Performance, Analysts See Smooth Sailing</a>
<h2 class="wp-block-heading">AI, Yield Management &amp; A &#8216;Magic Kingdom&#8217; At Sea</h2>
Carnival's revenue play isn't just about record bookings, it's about smart pricing. Enter &#8216;YODA&#8217; the company's AI-driven yield management system, designed to maximize revenue. Early results look promising, with new-to-cruise guests up 13% year-over-year and repeat bookings climbing 10%.
Meanwhile, Carnival is expanding its strategic destination assets, with the upcoming Celebration Key, set to open in mid-2025. By 2030, the company aims to handle 11 million guests annually—nearly double the 6.5 million expected in 2024. Daily capacity across its destinations will rise to 95,000, rivaling the foot traffic of Disney's Magic Kingdom.
<h2 class="wp-block-heading">Balance Sheet Detox</h2>
Debt reduction remains a priority, with Carnival slashing $7.3 billion in debt since early 2023. Interest expenses are already down 15% year-over-year, with CFO David Bernstein targeting a return to sub-3.5x leverage by FY26, a significant improvement from 6.7x in FY23.
<h2 class="wp-block-heading">Industry Implications: FX, Fuel &amp; Competitive Positioning</h2>
While Carnival is executing its multi-year plan, foreign exchange and fuel volatility remain headwinds for the broader industry. JPMorgan has adjusted (lowered) its earnings models for key competitors Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) and Norwegian Cruise Line Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) based on recent currency shifts and fuel cost increases. 
<h2 class="wp-block-heading">Investor Takeaway</h2>
Carnival is more than 80% of the way to its <a href="https://www.prnewswire.com/news-releases/carnival-corporation--plc-reports-second-quarter-2023-earnings-and-sets-sights-on-2026-sea-change-program-301862616.html">SEA Change</a> transformation targets, with long-term return on invested capital (ROIC) expected to land "at least in the teens" by 2026. With disciplined growth, AI-driven revenue strategies, and a revamped balance sheet, Carnival looks well-positioned to navigate the next phase of industry expansion. 
Investors betting on the cruise rebound might find Carnival's multi-year story compelling, especially as it leans into pricing power, brand execution and strategic destinations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42490038/norwegian-cruise-line-benefits-from-re-energized-consumer-spending-and-cost-savings-program-analyst-says">Norwegian Cruise Line Benefits From Re-energized Consumer Spending And Cost Savings Program, Analyst Says</a></li>
</ul>

Analyst Color

Entertainment

Long Ideas

Travel

Analyst Ratings

Trading Ideas

General

NCLH

Carnival's Transformation: AI-Driven Yields And A Balance Sheet Reset

Comerica Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) shares are trading lower in premarket Wednesday after the <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000028412/000002841225000005/cma-20250122.htm" rel="noreferrer noopener">fourth-quarter FY24 earnings result</a>.
The financial services company reported a fourth-quarter revenue increase of 5.5% to $825 million, missing the analyst consensus estimate of $837.98 million.
Net interest income increased $41 million to $575 million quarter-on-quarter, reflecting a strategic growth in core interest-bearing deposits and relationship-focused pricing.
Adjusted EPS of $1.20 also <a href="https://www.benzinga.com/earnings">missed the consensus estimate of $1.28.</a>
Average loans in the fourth quarter amounted to $50.62 billion and the return on average assets stood at 0.85%. Efficiency ratio for the quarter was 69.51.
Nonperforming assets increased $58 million to $308 million, or 0.61% of total loans and foreclosed property, compared to 0.50% in the third quarter of 2024.
The company held $850 in cash and equivalents as of December 31, 2024.
Curtis C. Farmer, Comerica Chairman and Chief Executive Officer, stated, &#8220;As expected, loans were pressured by paydowns in Commercial Real Estate, but we saw promising signals across other businesses that support our outlook for growth in 2025. Although some uncertainty remains, we believe customer sentiment is generally more optimistic about the future of the economy and plans for increased investment in their businesses.&#8221;
Outlook: Comerica <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000028412/000002841225000005/cma-20250122.htm" rel="noreferrer noopener">sees </a>FY25 net interest income growth of 6% &#8211; 7%, including the impact of BSBY cessation.
For the first quarter, the company expects net interest income to decline 1% &#8211; 2% sequentially, including the impact of BSBY cessation.
The company targets share repurchases at approximately <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$50 million in the first quarter of 2025</a>.
Price Action: CMA shares traded lower by 1.78% at $65.20 in premarket at the last check Wednesday.
Image: Shutterstock/ fizkes.

Equities

News

Guidance

Movers

Comerica Q4 Earnings: Revenue And EPS Fall Short Amid Loan Pressures, Eyes 2025 Growth

Real Estate

PGRE

Paramount Group Sells 45% Interest In 900 Third Avenue Office Building At Gross Asset Valuation Of $210M

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 08:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Amphenol beat estimated earnings by 10.0%, reporting an EPS of $0.55 versus an estimate of $0.5.
Revenue was up $990.00 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.05 in the previous quarter, leading to a 2.0% increase share price change the next day.
Here's a look at Amphenol's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.45</td>
<td>0.41</td>
<td>0.37</td>
<td>0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.50</td>
<td>0.44</td>
<td>0.40</td>
<td>0.41</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.80B</td>
<td>3.39B</td>
<td>3.10B</td>
<td>3.15B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>4.04B</td>
<td>3.61B</td>
<td>3.26B</td>
<td>3.33B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Amphenol management provided guidance for Q1 2025, expecting earnings between $0.49 and $0.51 per share.
To track all earnings releases for Amphenol <a href="https://www.benzinga.com/quote/APH/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Amphenol Earnings Review: Q4 Summary

Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) (the "Company") today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 2,600,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a purchase price of $1.70 per share in a registered direct offering.
The aggregate gross proceeds to the Company of this offering are expected to be approximately $4,420,000. The transaction is expected to close on or about January 23, 2025, subject to the satisfaction of customary closing conditions.
Univest Securities, LLC is acting as the sole placement agent.

Offerings

HUSA

Houston American Energy Corp. Announces $4.42M Registered Direct Offering Of 2.6M Shares Of Common Stock At A Price Of $1.70/Share

LOBO

Lobo EV Technologies Entered Into a Letter Of Intent With Roundtree Lab To Manufacture Smart Electric Medical Transport Beds

Decent Holding Inc. (the "Company"), an established wastewater treatment services provider in China, today announced the pricing of its initial public offering (the "Offering") of 1,250,000 ordinary shares (the "Ordinary Shares") at a public offering price of $4.00 per share. The Company expects to receive aggregate gross proceeds of $5 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on January 22, 2025, under the ticker symbol "DXST". The Offering is expected to close on January 23, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters an option (the "Over-Allotment Option"), within 45 days from the closing date of the Offering, to purchase up to an additional 187,500 Ordinary Shares at the public offering price, less underwriting discounts, to cover the Over-Allotment Option, if any.
The net proceeds from the Offering will be used for (i) business expansion; (ii) research and development; (iii) promoting the river water quality management service and expanding the treatment scope of river water; (iv) development and upgrade of wastewater treatment technology; and (v) recruiting talents in research and development and management.

IPOs

DXST

Decent Holding Inc. Announces Pricing Of $5M Initial Public Offering Of 1.25M Shares At A Price Of $4/Share

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Says Its ART100 Systems Have Been Delivered To Glo-Med Networks And Are Preparing For Deployment At A US Hospital

Ormat Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>), a leading geothermal and renewable energy company, today announced the signing of a 10-year Power Purchase Agreement (PPA) with Calpine Energy Solutions, one of North America's largest energy suppliers. Under this agreement, Calpine Energy Solutions will purchase up to 15 megawatts (MW) of clean, renewable energy from the Mammoth 2 geothermal power plant located near Mammoth Lakes, California, to support demand within its retail portfolio.
Energy deliveries under the PPA are set to begin in the first quarter of 2027 and will replace the existing PPA with the Southern California Edison Company (SCE). Notably, the new PPA, which includes an increase in production capacity and a higher price point, highlights the tight supply-demand balance of carbon-differentiated electricity in California, driven by state Renewable Portfolio Standards (RPS) compliance needs and voluntary corporate demand.

Ormat Technologies Announces 10-Year PPA With Calpine Energy Solutions For Up To 15MW From Mammoth 2 Geothermal Plant Starting Q1 2027; Replacing Southern California Edison Deal, Reflecting California's Carbon-Differentiated Electricity Demand

The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) reported upbeat fourth-quarter results on Tuesday.
Revenue rose 20% year over year to $5.33 billion, beating the consensus of $5.19 billion.
Net interest revenue rose 19% Y/Y to $2.531 billion in the fourth quarter. Clients' daily average trades totaled 6.312 million, up 22% Y/Y.
Adjusted net income rose 44% Y/Y to $1.97 billion. Adjusted EPS increased 49% to $1.01, beating the consensus of $0.91.
Total client assets rose 19% Y/Y to $10.10trillion. The company's active brokerage accounts reached 36.5 million in the quarter.
Mike Verdeschi, CFO, said, "Client transactional sweep cash grew by $35 billion versus 3Q24, including a $25 billion increase in December due to typical year-end seasonality. This build helped us further reduce Bank Supplemental Funding by $14.9 billion to $49.9 billion – down ~50% from peak levels."
Charles Schwab shares gained 5.9% to close at $80.93 on Tuesday.
These analysts made changes to their price targets on Charles Schwab following earnings announcement.
<ul>
<li>Wells Fargo analyst Michael Brown upgraded Charles Schwab from Equal-Weight to Overweight and raised the price target from $89 to $93.</li>
<li>Barclays analyst Benjamin Budish maintained the stock with an Overweight and raised the price target from $95 to $96.</li>
<li>Citigroup analyst Christopher Allen maintained Charles Schwab with a Neutral and raised the price target from $80 to $85.</li>
<li>Deutsche Bank analyst Brian Bedell maintained Charles Schwab with a Buy and boosted the price target from $98 to $105.</li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="492" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-1024x492.png" alt="" class="wp-image-744746" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-1024x492.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-300x144.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154-768x369.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22083203/image-154.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43123084/top-3-health-care-stocks-that-could-blast-off-this-quarter">Top 3 Health Care Stocks That Could Blast Off This Quarter</a></li>
</ul>

Price Target

Markets

SCHW

Charles Schwab Analysts Increase Their Forecasts After Upbeat Results

BDMD

Baird Medical Investment Holdings Is Expanding Its Presence Into San Francisco

<h3 class="wp-block-heading">Tech Stocks In Focus</h3>
On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is a quantum stock. &#8220;If you want to participate in a short squeeze, this is better <a href="https://www.benzinga.com/quote/RGTI">than most,&#8221; he added</a>.
Shares of quantum stocks, including Rigetti Computing, rose sharply on Tuesday amid strength in tech and AI stocks as investors assessed the new administration&#8217;s policies and AI efforts.
Cramer recommended buying ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), adding that it is a &#8220;remarkably great&#8221; company.
Supporting his view, Wells Fargo analyst Joseph Quatrochi, on Jan. 13, maintained ASML with an Overweight and raised the price target from $790 to $860.
Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is a &#8220;great&#8221; company, Cramer said. &#8220;I do think that there's a lot of people who believe that they will not be able to deliver on this quarter. I, therefore, am reluctant to get in ahead of the quarter.&#8221;
AMD will report fiscal fourth quarter and full year 2024 financial results after the closing bell on Tuesday, Feb. 4. Analysts expect the company to report quarterly earnings at $1.09 per share, up from 77 cents per share in the year-ago period.
<h3 class="wp-block-heading">Hold On To This Stock</h3>
The &#8220;Mad Money&#8221; host recommended to hold on to Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>). &#8220;I don't want to sell it here, we might be at some sort of trough at this very moment in Dow pricing,&#8221; he added.
Recently, on Jan. 13, Morgan Stanley analyst Vincent Andrews also maintained Dow with an Equal-Weight rating and cut the price target from $59 to $46.
<h3 class="wp-block-heading">Discusses His View On Health Care Stocks</h3>
Cramer said Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) is not his favorite and considers Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) as the better bet for this group.
Adding support to Cramer's view, Stifel analyst Jonathan Block, on Jan. 7, lowered the price target on the stock from $20 to $18.
Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) is losing a lot of money and is &#8220;just a total spec,&#8221; Cramer said.
On Nov. 6, Clover Health Investments reported worse-than-expected third-quarter revenue results.
Price Action:
<ul>
<li>Rigetti Computing shares jumped 42.2% to settle at $13.98 on Tuesday.</li>
<li>ASML shares gained 0.9% to close at $763.00 during the session.</li>
<li>AMD shares gained 0.7% to close at $122.28.</li>
<li>Dow shares gained 1.3% to settle at $41.58 on Tuesday.</li>
<li>Elanco Animal Health shares gained 0.2% to close at $12.04.</li>
<li>Clover Health Investments shares rose 3.9% to settle at $4.24 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43096091/jim-cramer-this-tech-stock-is-a-buy-louisiana-pacific-has-been-a-great-stock">Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A &#8216;Great Stock&#8217;</a></li>
</ul>
Image: Shutterstock

Tech

Media

ASML

CHWY

CLOV

ELAN

RGTI

Jim Cramer: AMD Is A 'Great' Company, Hold Onto Dow Inc.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feqs-cockpit.com%2Fcgi-bin%2Ffncls.ssp%3Ffn%3Dredirect%26url%3D5a17290acfd416e9e07b3d92a8056cf5%26application_id%3D1862413%26site_id%3Dairport_aws%26application_name%3Dnews&amp;esheet=54185193&amp;newsitemid=20250122434451&amp;lan=en-US&amp;anchor=Teradyne+Robotics&amp;index=1&amp;md5=66f9217e1043b5d0e28297d01da918dd">Teradyne Robotics</a>, a division of Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) and global leader in advanced robotics solutions, and Analog Devices, Inc. (ADI), a global semiconductor leader, today announced a strategic partnership aimed at accelerating the development and usage of advanced robotics.
Teradyne Robotics, which includes Universal Robots (UR) and Mobile Industrial Robots (MiR), will partner with ADI to develop and deploy robots, AI and software in support of ADI's collaborative automation initiative, which aims to enhance safety, efficiency and optimize fabrication and backend operations through automation. These solutions will address key challenges facing the semiconductor market, including ergonomic issues due to highly repetitive tasks, manufacturing downtime, insufficient workforce, and real estate constraints.

Teradyne Robotics Partners With Analog Devices To Accelerate Advanced Robotics Development For Semiconductor Market

WIIM

QBTS

D-Wave Quantum shares are trading higher after the company revealed a new program to fast-track the deployment of quantum computing applications.

MGTX

MeiraGTx Granted FDA Rare Pediatric Disease Designation For AAV8-RK-RetGC In Leber Congenital Amaurosis Due To GUCY2D Mutations

Prominent Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) critic Peter Schiff reignited debates on the crypto king&#8217;s legitimacy by labeling it a meme coin <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43123173/3-reasons-why-bitcoin-could-hit-122000-soon-10x-research">devoid of intrinsic value</a>.
What Happened: Schiff on Tuesday on X <a href="https://x.com/PeterSchiff/status/1881783737584906551">responded</a> to Anthony Pompliano's explanation of meme coins, stating that there's little to distinguish Bitcoin from newer meme assets like TRUMP.
"It's a fine line to walk when explaining a meme coin without exposing the same fraud about Bitcoin," he added. He <a href="https://x.com/PeterSchiff/status/1881770557223682309">stated</a>, "Bitcoin is a meme coin."
Schiff's post sparked debate across Crypto Twitter, with some comparing Bitcoin to gold. 
Bitcoin podcast host Walker argued, "The meme is perfected sound money that is superior to gold" and claimed Bitcoin is gradually <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42935597/mark-cuban-advocates-bitcoin-over-gold-during-economic-turmoil-i-think-it-has-more-value-than-gold">demonetizing gold</a>.
CryptoQuant CEO Ki Young Ju took it further, calling gold a "meme asset," with 90% of its valuation stemming from narrative belief. 
He concluded, "Goldbugs are no different from Bitcoin maxis."
Schiff dismissed the comparisons, reiterating that gold's value is rooted in tangible properties, unlike Bitcoin, which he called &#8220;fool&#8217;s gold.&#8221;
Schiff's detractors reminded him of past predictions, including his claim that Bitcoin would never reach $100,000, and asked what he would say if it hit $1 million. 
One trader quipped, "Peter Schiff wouldn't exist without Bitcoin," to which Schiff retorted that he was well-known before Bitcoin.
Also Read: <a href="https://www.benzinga.com/25/01/43078360/peter-schiff-gets-sarcastic-wonders-whether-biden-will-sell-some-bitcoin-on-last-day-of-presidency">Peter Schiff Says &#8216;Last Night&#8217; For Biden To Sell Some Bitcoin Before Trump Takes Over: &#8216;Let&#8217;s See If He Takes Advantage Of The Opportunity&#8217;</a>
Why It Matters: Schiff has consistently expressed concern over what he perceives as a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42878139/peter-schiff-doesnt-hate-bitcoin-but-warns-millions-will-lose-more-than-they-can-afford-in-speculative-mania">speculative mania surrounding cryptocurrencies</a>, warning it could harm the principles of sound money. 
While he insists he doesn't hate Bitcoin, he cautioned that millions might lose more than they can afford.
In December 2024, Schiff argued <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42392610/peter-schiff-bitcoin-is-a-threat-to-the-us-and-public-enemy-number-one">Bitcoin could become a "public enemy"</a> if the government squandered taxpayer money on it, describing it as the riskiest asset.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43123173/3-reasons-why-bitcoin-could-hit-122000-soon-10x-research">3 Reasons Why Bitcoin Could Hit $122,000 Soon: 10x Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

'Bitcoin Is A Meme Coin' Says Peter Schiff, Critics Clap Back: 'Goldbugs Are No Different From Bitcoin Maxis'

<a href="https://www.globenewswire.com/Tracker?data=T8uscBjMZ3PQs7RRv2I2QhSiQsH6XlJSkrW74rd7kj9oDlKXDlgfEjAs624j5QKkV1AQbadb2wEypzjTMzs-z2dzt7eErpuowSFIrPM8c5A=">Scorpius Holdings, Inc</a> (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced its collaboration with KaloCyte, a pioneering pre-clinical company in the field of therapeutic innovation. Under this initial project, Scorpius will utilize its scientific and technical expertise to enhance manufacturing efficiencies for KaloCyte's lead candidate, ErythroMer&#x2122;, a dried, bio-inspired artificial red blood cell designed to address life-threatening blood loss in situations where stored red blood cells are unavailable, unsuitable, or in short supply. The two companies are also evaluating opportunities to establish a commercial-scale manufacturing agreement.

Biotech

SCPX

Scorpius Announces Collaboration With KaloCyte To Enhance Manufacturing For ErythroMer, Evaluating Commercial-Scale Manufacturing Agreement

Oppenheimer analyst Brian Schwartz maintains Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) with a Outperform and lowers the price target from $150 to $135.

AGYS

Oppenheimer Maintains Outperform on Agilysys, Lowers Price Target to $135

Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This application, focused on its lead asset SPC-15, highlights Silo's commitment to advancing treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (PTSD).
The provisional patent covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs) to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia. This filing adds to Silo's growing portfolio of pending patents for SPC-15 technology, originally licensed through a collaboration with Columbia University. This exclusive agreement enables Silo to develop, manufacture, and commercialize SPC-15 globally.

SILO

Silo Pharma Announces Provisional Patent Filing For SPC-15 Targeting NMDARs And 5-HT4Rs For Stress-Induced Psychiatric Disorders; Advances Collaboration With Columbia University

C3.Ai shares are trading higher after the company announced a partnership with McKinsey to drive rapid and scalable AI solutions for global enterprises.

Comments

Shapeways Holdings

News

Latest news for Shapeways Holdings (OTC:SHPSQ) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga